MB and B-cell non-Hodgkin lymphoma: We observed a 3.5- to 5-fold increase in the 89Zr-hCD4-Mb uptake within hCD4+ HPB-ALL tumors compared with hCD4- DHL B-cell lymphomas at 6, 24, and 48 h post tracer injection (Figure 2A, 2C-D; Figure S2C).